Dr. Yang Xueyong is a nationally recognized leader in pediatric congenital heart disease (CHD) surgery, renowned for his expertise in minimally invasive techniques and compassionate patient care. With over 30 years of clinical experience, he has performed 6,000+ cardiac surgeries (3,000+ as lead surgeon), achieving a 97% 5-year survival rate for complex CHD cases. Dr. Yang pioneered the right subaxillary mini-incision approach for infants as young as 15 days old and weighing as little as 750 grams. A dedicated advocate for equitable healthcare, he has led 20+ national CHD screening campaigns in underserved regions, providing life-saving surgeries to 200+ impoverished children free of charge. Honored as a "9958 Angel Expert" by the China Red Cross Foundation, Dr. Yang is celebrated for blending surgical precision with deep humanitarian commitment.
1. Minimally Invasive Cardiac Surgery
Right subaxillary mini-incision repair for:
Ventricular septal defect (VSD)
Tetralogy of Fallot (TOF)
Transposition of the great arteries (TGA)
Outcomes: 93.5% survival rate in infants <10 kg, 7-day average hospital stay.
2. Critical CHD Management
Emergency neonatal surgery ("Golden 6-Hour Rule" for critical cases).
Modified ultrafiltration (MUF) to reduce post-bypass inflammation.
3. Multidisciplinary Care
Family-integrated ICU protocols, reducing postoperative anxiety by 55%.
5G real-time surgical updates for families (99% satisfaction rate).
PhD in Cardiothoracic Surgery
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS/PUMC), Beijing, China
Advisor: Prof. Yinglong Liu (Founder of China’s pediatric cardiac surgery discipline)
Postdoctoral Fellowship in Neonatal Critical Care
Beijing Pediatric Research Institute
Advisor: Prof. Zhichun Feng (Neonatal resuscitation and perioperative management)
Clinical Training
Senior Visiting Scholar, Boston Children’s Hospital (2016, congenital heart defect repair techniques)
1. Innovative Surgical Techniques
Developed robot-assisted right subaxillary approaches (Da Vinci system), reducing operative time by 20%.
National Key Project: Three-Tiered CHD Prevention System (prenatal screening to rehabilitation).
2. Genomic and Precision Medicine
Identified miR-26b as a regulator of pulmonary hypertension in VSD (published in Pediatric Research, IF=3.6).
Collaborated on CRISPR-based fetal gene editing for 22q11.2 deletion syndrome (60% success in animal models).
3. Health Systems Optimization
AI-driven postoperative follow-up platform: 92% complication detection sensitivity.
Mandarin (Native)
Medical English (Proficient in academic writing and international collaboration)
Yang X, Liu Y. (2023). Right Subaxillary Mini-Incision in Neonatal CHD: A Decade of Refinement. Ann Thorac Surg 115(2): 321-322.
Yang X, et al. (2021). miR-26b Modulates Pulmonary Vascular Remodeling in VSD-Associated PAH. Pediatr Res 89(4): 876-883.
Co-authored National Guidelines for CHD Emergency Surgery (2024 Edition).
Chief Editor: Essentials of Congenital Heart Disease (2022), adopted by 50+ medical schools.
Rating: ⭐⭐⭐⭐✨ (4.8/5) on Haodf.com (China’s leading healthcare platform)
Volume: 5,080+ patient consultations, 1,200+ reviews.
Representative Feedback:
“Dr. Yang saved my daughter’s life with a 2cm incision—she’s now a lively 5-year-old!” – Parent of a TOF patient.
“His team explained every step via video during surgery. We felt informed and trusted.” – Father of a neonatal TGA case.
“Free surgery gave my child a future. We’ll never forget his kindness.” – Recipient of "Angel Journey" charity program.
EN
CN
